Table 5

Adverse events possibly or probably related to daptomycina

Age range (yr), sexWt (kg)Underlying disease(s)bDAP dosecAdverse eventOnset of event/total DAP duration (days)DAP DCOutcome
31–50, M141CLCR of 30 to <50, OM, DM, HTN, GI disease (no statin)6 mg/kg q24hCPK increase8/13YesResolved
51–65, F71CLCR of 30 to <50, HTN, COPD, anemia/hematologic disease, acute renal failure, solid organ cancer (no statin)6 mg/kg q24hCPK increase7/11YesResolved
51–65, F85CLCR of <304 mg/kg q48hVaginal candidiasis8/unknowndNoUnknown
66–80, M80CLCR of <30 ml/min, IE, cardiac arrhythmias, HTN, COPD, renal disease6 mg/kg q48hAnemia1/7NoResolved with residual effects
  • a None of the reported adverse events were serious. Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CLCR, creatinine clearance; CPK, creatine phosphokinase; DAP, daptomycin; DC, discontinued; GI, gastrointestinal; CV, cardiovascular; HTN, hypertension; PVD, peripheral vascular disease; IE, infective endocarditis; OM, osteomyelitis; DM, diabetes mellitus; M, male; F, female.

  • b Start-of-treatment and end-of-treatment CLCR groups did not change for the 4 patients during daptomycin therapy.

  • c Initial and final daptomycin doses did not change for the 4 patients.

  • d The patient was monitored for 19 days after the onset of the adverse event; nothing about the vaginal candidiasis outcome was documented.